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Maternal immunizationa b s t r a c t
Group B streptococcus, found in the vagina or lower gastrointestinal tract of about 10–40% of women of
reproductive age, is a leading cause of early life invasive bacterial disease, potentially amenable to pre-
vention through maternal immunization during pregnancy. Following a consultation process with global
stakeholders, the World Health Organization is herein proposing priority research and development
pathways and preferred product characteristics for GBS vaccines, with the aim to facilitate and accelerate
vaccine licensure, policy recommendation for wide scale use and implementation.
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transplacental transfer of maternal Group B streptococcus (GBS)
antibodies and infant protection from invasive infection was
shown, supporting the concept of a maternal immunization-
based prevention strategy [1]. GBS, an encapsulatedbacterium found in the vagina or lower gastrointestinal tract
of about 10–40% of women of reproductive age, is a leading
cause of neonatal and infant invasive bacterial disease, often
leading to death or neurological sequelae. Ascending
infections during pregnancy can lead to stillbirths and
premature delivery, and GBS can cause puerperal sepsis and other
maternal morbidities [2]. Carriage or risk factor-based screening
followed by intrapartum antibiotic prophylaxis (IAP) can reduce
the risk of GBS disease in the first week of life, but this approachdevel-
2 J. Vekemans et al. / Vaccine xxx (2018) xxx–xxxhas only been partially successful. It is ineffective in preventing
late-onset GBS infant disease, is associated with a substantial
amount of perinatal antibiotic use, and has not been implemented
on a systematic basis in most low- and middle-income countries.
There is a significant residual disease burden in high-income coun-
tries [3,4].
Past investments in GBS vaccine research have been limited,
probably due to a (mis)perception that IAP based strategies are suf-
ficient to deal with the disease in high-income countries, concerns
about the complexity of developing vaccines for use in pregnancy,
and an incomplete evidence base on the global disease burden.
New data, a better understanding of the limitations of existing con-
trol strategies and progress in the definition of regulatory and pol-
icy pathways for immunization during pregnancy have renewed
the interest in vaccine strategies against perinatal GBS disease
[5,6]. Considering the available evidence about the role of passively
transferred GBS antibodies from the mother to the neonate, the
technical feasibility of developing a GBS vaccine is estimated to
be high [7,8]. In line with its mission to provide guidance on
research and development pathways targeting diseases of high
public health interest, the World Health Organisation has just
made two technical documents publically available: a GBS vaccine
development technology roadmap presenting a priority action
framework, and preferred product characteristics [9]. The aim is
to facilitate and accelerate vaccine development and guide the
work of researchers, industry and funders with respect to clinical
development data collection requirements, ensuring that critical,
relevant public health questions are answered. The intent of this
work is to support robust policy decision-making for licensed
products to be practically implemented where most needed, with-
out undue delays.
As expressed in these documents, the strategic goal is to see the
development and licensure of safe, effective and affordable GBS
vaccines for maternal immunization during the second or third tri-
mester of pregnancy to prevent GBS-related stillbirth and invasive
GBS disease in neonates and young infants, appropriate for use in
high-, middle- and low-income countries. A target of 80% protec-
tion against the combined risk of laboratory-confirmed GBS still-
birth and invasive disease in the offspring was set.
Among the research priorities, more and better data are needed
to quantify the precise potential public health impact of a GBS vac-
cine. Very little information is available from some of the poorest
world regions. The vaccine composition will need to overcome
the diversity of bacterial capsular types or target protein expres-
sion prevalence and polymorphism, targeting at least 90% of the
current invasive disease isolates. Long-term strain composition
monitoring should be planned and the potential for capsular
switching, strain evolution and replacement of the bacterial popu-
lation as a cause of invasive disease considered. In line with prin-
ciples of safety precaution, there is a preference for an adjuvant-
free formulation, although the inclusion of an aluminium salt or
another adjuvant with an extensively demonstrated favourable
safety profile in pregnancy would likely be acceptable.
Detailed determinants of immunogenicity in pregnant women
and antibody transfer to offspring should be characterized. There
is a clear preference for a one-dose regimen. The role of past natu-
ral GBS exposure, of a priming dose, of boosters during subsequent
pregnancies will need to be defined. Immunogenicity upon co-
administration with recommended vaccines for use in pregnancy,
and impact on immune responses to relevant infant vaccines (con-
sidering both the target antigen and potential presence of similar
protein carriers) need to be evaluated.
The development of a quality-assured, regulatory-acceptable
immune correlate of protection could accelerate and would reduce
the cost of vaccine development. Further assay development,
detailed immuno-epidemiological and vaccine studies are neededPlease cite this article in press as: Vekemans J et al. Maternal immunization aga
opment technological roadmap and preferred product characteristics. Vaccineto confirm whether, in addition to favourable safety being estab-
lished, large pre-licensure efficacy trials are needed, or whether
it would be acceptable for licensure and policy decision to be based
on indirect evidence of efficacy, with more comprehensive health
impact evaluation ongoing after initial licensure, such as during
pilot implementation projects.
In the absence of evidence that supports licensure based on
immune correlates of protection, a pivotal efficacy trial will be
needed. Endpoint case definitions and ascertainment methodolo-
gies will need to be defined and standardized, including in the case
of stillbirth or fatality. Priority endpoints are presented. Leading
principles about appropriate standards of care for maternal and
infant infectious risk management in the context of a GBS vaccine
efficacy trial are proposed, in due consideration of local standards
of care and WHO recommendations on infection risk management.
The influence of important maternal comorbidities such as HIV
infection and malaria in pregnancy on vaccine outcomes should be
evaluated. Considering the high prevalence of HIV infection in cer-
tain regions with high GBS disease incidence, and the much
increased risk of invasive GBS disease in HIV-exposed infants,
HIV should not be a contra-indication to vaccination.
Robust clinical development planning, data collection and
delivery will require constitution of networks of investigators,
including research centres in low- and middle-income countries
with strong clinical trial research capacity, documented baseline
rates of disease and of common adverse obstetric and neonatal
outcomes, and appropriate regulatory and ethical oversight. Global
recommendations and resources are available to support adequate
assessment of the safety of vaccines for use in pregnancy. The
maternal immunization delivery platform needs to be rationalized
based on a long-term vision, considering the various disease tar-
gets and the need for integrated prenatal care.
The cost of research, production, procurement and delivery
must be manageable and ensure that when available, there are
no access barriers for products that meet critical medical needs,
and no time gap between low- and high-income countries. The
residual disease burden in high-income countries should be re-
assessed, with due consideration of adverse consequences of IAP-
associated perinatal antibiotic use. Precise estimates of the global
health economic value of resources and efforts spent on GBS vac-
cine development should guide responsible public and private
investments. Funding partnerships may be required. In terms of
approval and implementation, the WHO prequalification and SAGE
policy recommendation pathway, complementary to national reg-
ulatory licensure, provide a way to ensure programmatic suitabil-
ity and constitute a requirement for some financing and
procurement agencies.Ethics committee approval
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